An Integrated Clinical Genomic and Transcriptomic Subgrouping of Central Chondrosarcoma.

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Central conventional chondrosarcoma is the second most common bone sarcoma, with histological grade predicting survival.
• Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes produce oncometabolites affecting DNA methylation and cell differentiation.
• Current classification based solely on IDH status is insufficient due to distinct DNA methylation profiles and potential subgroups.

Purpose of the Study:

• To identify biological subgroups in 116 chondrosarcomas using integrated clinical, IDH mutation, gene expression, and loss of heterozygosity (LOH) data.
• To explore clinical associations and genomic differences between IDH-mutant and IDH-wild-type chondrosarcomas.
• To investigate transcriptomic profiles for further subgroup identification.

Main Methods:

• Integrated analysis of clinical data, IDH mutation status, RNA sequencing, and genome-wide LOH in 116 chondrosarcoma samples.
• Comparative analysis of LOH extent between IDH-wild-type and IDH-mutant tumors.
• Clustering of RNA expression data for differentiation markers to identify transcriptomic subgroups.

Main Results:

• Clinical associations found between sex, histological grade, tumor site, and IDH mutation status.
• RNA sequencing and LOH confirmed distinctions between IDH-wild-type and IDH-mutant tumors, with higher LOH in wild-type.
• Transcriptomic profiling identified subgroups with chondrogenic, osteogenic, resting chondrocyte, or dedifferentiated profiles, each with specific clinical presentations.

Conclusions:

• Chondrosarcoma classification solely on IDH status is an oversimplification.
• Integrated analysis reveals complex clinical, genomic, and transcriptomic patterns.
• Identified subgroups suggest different precursor cells and may guide future treatment stratification for chondrosarcoma.